인간 간 세포와 면역 세포를 이용한 인간화 마우스 모델 개발

Executive Industry Relevance

The dual humanized mouse model enables mechanistic de-risking of liver-targeted therapeutics by providing a disease-relevant system for studying human liver-immune interactions. This supports target validation and predictive confidence in preclinical development, particularly for HIV-associated liver pathogenesis and related immunomodulatory therapies. The model enhances translational continuity from discovery through preclinical evaluation.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Interrogates therapeutic hypotheses involving human liver and immune cell crosstalk in vivo.
• Operational Value: Provides a disease-relevant system for functional target validation of immunomodulators and antivirals.
• Predictive Value: Supports portfolio triage by reducing mechanistic ambiguity in liver pathogenesis models.

Screening & Assay Development

• Scientific Value: Prepares validated biological systems with stable human liver engraftment for downstream compound screening.
• Operational Value: Enables assay standardization through reproducible human immune cell differentiation in the bone marrow niche.
• Scalability: Supports platform reuse for evaluating liver-tropic compounds and immune modulators.

Translational & Preclinical Research

• Scientific Value: Maintains disease relevance by modeling human-specific liver and immune interactions in a living organism.
• Operational Value: Ensures continuity from discovery through preclinical validation via stable chimeric organoid formation.
• Risk Mitigation: Informs risk-adjusted advancement decisions by capturing human-specific toxicity and efficacy signals.

Pipeline & Workflow Integration

The model integrates into the discovery continuum from target validation through lead identification to preclinical efficacy testing, particularly for liver-directed immunomodulatory therapies.

• Discovery Biology: Supports hypothesis testing of liver-immune pathway modulation in a humanized context.
• Screening: Delivers assay readiness through reproducible splenic engraftment and circulating human immune cell generation.
• Analytics: Enables quantitative measurement of human albumin, cytokine profiles, and immune cell subsets as translational biomarkers.
• Translational Research: Connects to preclinical continuity via stable human hepatocyte and leukocyte chimerism over extended periods.
• Enterprise Reuse: Functions as a reusable platform for multiple therapeutic areas including virology, immunology, and metabolic disease.

Operational & Enterprise Impact

• Scientific Value: Predictive confidence in target validation through reduction of species-specific mechanistic ambiguity.
• Operational Value: Standardization and reproducibility via defined splenic injection and spleen ligation protocol.
• Strategic Value: Better go/no-go decisions by identifying liver-specific immune-mediated toxicities early.
• Portfolio Impact: Risk-adjusted prioritization of candidates based on human liver and immune response profiles.

Implementation Considerations

• Requires expertise in murine surgery, cell handling, and sterile transplantation techniques.
• Dependent on immunodeficient TK-NOG mouse strain availability and preconditioning regimens.
• Necessitates cross-team standardization for cell preparation, injection volume control, and spleen ligation consistency.
• Adaptation considerations include variability in human donor cell engraftment efficiency across liver and HSPC sources.
• Practical limitations include model sustainability beyond 12–16 weeks and requirement for antiviral pretreatment to clear transgenic liver cells.

Biopharma FAQs